preventive-care

Preventive Schedule

Preventive Care Schedule — Ishamma T M

Patient: Ishamma T M | Age: 81 | Sex: Female
Active diagnoses: Acute Myeloid Leukemia (AML), on Azacitidine + Venetoclax

Patient is on active AML chemotherapy (Azacitidine + Venetoclax) causing immunosuppression. ALL vaccine decisions must be coordinated with the treating hematologist (Ashwin V Nair). Live vaccines are contraindicated.

Age-Appropriate Screenings

Screening Recommendation Status Notes
Mammography Individualized (USPSTF: not routine past 75) NOT DOCUMENTED Discuss with oncologist given AML prognosis
Colonoscopy / CRC screening Selective 76-85 (USPSTF) NOT DOCUMENTED Consider deferring during active chemo
DEXA (bone density) Recommended for women ≥65 NOT DOCUMENTED Assess osteoporosis risk
Blood pressure Annual NOT DOCUMENTED Monitor at clinic visits
Influenza vaccine Annual NOT DOCUMENTED CAUTION: verify timing relative to chemo cycles with hematologist
COVID-19 vaccine Per ACIP guidance NOT DOCUMENTED CAUTION: immunosuppressed — timing matters
Pneumococcal (PCV20) One-time if not done NOT DOCUMENTED CAUTION: immunosuppressed
Zoster vaccine (Zostavax) One-time ~2016 GIVEN (~2016, patient report) Efficacy likely waned (>8 yrs). Prior shingles history. See Herpes Zoster
Shingrix (shingles) 2-dose series ≥50 NOT GIVEN Recommended even after Zostavax. DEFER during active immunosuppression. Discuss timing with oncologist.
Falls risk assessment Annual NOT DOCUMENTED High priority given age + anemia
Vision/hearing Annual NOT DOCUMENTED
Depression screening Annual NOT DOCUMENTED
Diabetes monitoring (fructosamine) Every 4–6 weeks (preferred over HbA1c in AML) Last fructosamine: 2026-04-22 (310 µmol/L, HIGH). Last HbA1c: 2026-03-02 (5.7% — unreliable) Next fructosamine ~May 2026. HbA1c invalid due to AML-related RBC turnover. See Fructosamine, Diabetes Mellitus
Renal function Annual or per chemo protocol Last: 2026-04-06 (Cr 0.6) Current via chemo labs